Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 8.19B 7.18B 6.62B 6.2B 11.62B 773B 11.86B 79.57B 30.79B 382B 30.76B 30.09B 1,324B | P/E 2022 |
-13.6x | P/E 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 7.5B 6.57B 6.06B 5.67B 10.64B 707B 10.86B 72.82B 28.18B 349B 28.15B 27.53B 1,212B | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Reents
PSD | President | 59 | 31/07/2024 |
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 30/04/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 19/01/2021 |
Scott Reents
BRD | Director/Board Member | 59 | 31/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 31/07/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 31/07/24 | Bain Capital Private Equity LP
| Issuer sale | Company | 65,679,781 | 36.0492% | |
| 31/07/24 | Issuer sale | Executive/Senior Manager | 222,723 | 0.1222% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +38.04% | 8.19B | |
| +0.33% | +1.37% | +63.66% | +123.67% | 55.63B | |
| +0.82% | +15.05% | +79.52% | +88.67% | 52.25B | |
| +1.36% | +0.36% | -14.52% | -14.67% | 23.07B | |
| -1.04% | +7.91% | +3.91% | +413.05% | 22.41B | |
| +5.69% | +13.86% | +36.45% | -2.64% | 17.32B | |
| -1.10% | +4.00% | +29.97% | -32.75% | 15.94B | |
| +2.89% | +5.51% | +25.42% | +188.41% | 13.77B | |
| -3.35% | +8.96% | +134.32% | +282.61% | 13.47B | |
| +6.79% | +14.07% | +36.80% | - | 12.43B | |
| Average | +1.37% | +4.30% | +39.55% | +120.49% | 23.45B | |
| Weighted average by Cap. | +1.04% | +4.95% | +47.66% | +119.67% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -352M -308M -284M -266M -499M -33.16B -509M -3.41B -1.32B -16.39B -1.32B -1.29B -56.83B | -433M -380M -350M -328M -614M -40.83B -627M -4.2B -1.63B -20.18B -1.63B -1.59B -69.97B |
| Net Debt | -523M -459M -423M -396M -742M -49.36B -758M -5.08B -1.97B -24.39B -1.96B -1.92B -84.59B | -695M -610M -562M -526M -987M -65.6B -1.01B -6.76B -2.61B -32.42B -2.61B -2.55B -112B |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Select your edition
All financial news and data tailored to specific country editions
